Egyptian Vaccine Manufacturers Alliance

What Egyptian Vaccine Manufacturers Alliance does

The Egyptian Vaccine Manufacturers Alliance (EVMA) is a government-established strategic initiative created by Prime Minister's Decree No. 719 of 2024 to coordinate the localization of vaccine manufacturing in Egypt and position the country as a regional manufacturing hub for Africa. It is not a commercial enterprise but a convening and alignment body operating under the governance of the Medical Industries Localization Committee, with the Unified Procurement Authority (UPA) serving as rapporteur on behalf of the Prime Minister. EVMA brings together the Ministry of Health and Population (MOHP), the Egyptian Drug Authority (EDA), the UPA, six domestic vaccine manufacturers (VACSERA, Biogeneric Pharma/BPG, Gennvax, VBC Vaccines & Biologicals City, Gypto E., and EVA Pharma), and international technology transfer providers (Aspen, Bilthoven Biologicals, Minhai, Kangtai) under a unified national strategy.

EVMA's core offerings center on coordination, capacity building, and market access rather than on proprietary technology products. The EVMA-RCCN (Regional Capacity Building Center) delivers biomanufacturing workforce training covering upstream and downstream processing, quality control and assurance, Good Manufacturing Practices (GMP), and regulatory compliance, with curriculum integration into Cairo University and Ain Shams University degree programs. Additional offerings include regulatory capacity building to harmonize standards with the African Union's 2040 localization target, joint R&D collaboration between manufacturers and universities, and facilitation of WHO Prequalification for Local Vaccine Manufacturers to enable export to AU member states. Distribution is institutional and government-to-government: the UPA handles procurement of locally manufactured vaccines for Egypt's national immunization program, and planned African continental access flows through bilateral agreements and PAVM alignment.

The business model is non-commercial. EVMA does not book revenue; financial flows occur between member manufacturers and the UPA via public procurement contracts, with EVMA serving as the alignment and convening layer. The organization's strategic value is policy-driven — decree-backed institutional authority to synchronize government, regulator, and manufacturer activity — and its growth signal is measured by committee activity, training program scale, and export channel development rather than by revenue or headcount.

Name

Egyptian Vaccine Manufacturers Alliance

Legal name

Egyptian Vaccine Manufacturers Alliance

Website

https://evma-egypt.org

Company type

Private

Founded year

2024

Operating status

Operating

Short description

EVMA is a government-established coordination body, created by Prime Minister's Decree in 2024, that convenes Egypt's Ministry of Health, regulators, and six vaccine manufacturers to localize production and support African public health markets.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing Coordination

NAICS

Public Administration (92)

SIC

Services-Management Services (8741)

akta.pro industry

PRIMARYHLAJAHAJ

Vaccine Policy, Advisory Committees & Program Governance

Healthcare & Life Sciences/Public Health, Government & Regulators/Immunization Programs & Vaccine Administration

SECONDARYHLAJAKAK

Global Immunization & Vaccine Access Alliances

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)

SECONDARYHLAJAOAF

Immunization & Vaccine Access Partnerships (Global Vaccine Alliances)

Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health Initiatives & Partnerships

SECONDARYBPAIAJAD

Immunization & Vaccination Programs Administration

Business & Public Services/Public Sector & Government Administration/Public Health Administration & Regulation

SECONDARYBPADANAJ

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation

Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation

Keywords

• Vaccine manufacturing localization
• Biomanufacturing workforce training
• Regulatory capacity building
• Public health coordination
• Vaccine technology transfer

Headquarters

HQ city

Cairo

HQ country

Egypt

HQ region

Africa

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Public Vaccine Procurement Contracts: EVMA coordinates with the Unified Procurement Authority (UPA) to facilitate procurement of locally manufactured vaccines for Egypt's national immunization program. Revenue flows through government contracts awarded to member manufacturers, with EVMA serving as the convening and alignment body rather than a direct revenue-generating entity.
2. African Market Export (Planned): EVMA aims to facilitate access to African markets for member manufacturers, supporting export of locally produced vaccines. This is a planned revenue stream aligned with the African Union's agenda 2063 and the Partnerships for African Vaccine Manufacturing (PAVM) initiative.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

EVMA is a government-established strategic coordination alliance that brings together Egyptian regulatory bodies, vaccine manufacturers, and international technology transfer partners to localize vaccine production in Egypt. Its core activities include mapping and strengthening member manufacturer capabilities, facilitating technology transfer, delivering biomanufacturing workforce training through the EVMA-RCCN center, supporting regulatory capacity building via the Egyptian Drug Authority, and coordinating access to African export markets in alignment with the African Union's Agenda 2063 and the WHO-supported PAVM initiative.

Product overview

EVMA is a strategic alliance (not a single product company) focused on enhancing vaccine production capabilities in Egypt and across Africa. The alliance provides coordination services among Egyptian vaccine manufacturers (VACSERA, Biogeneric Pharma/BPG, VBC Vaccines & Biologicals City, Gennvax, EVA Pharma, Gypto E.), government bodies (MOHP, UPA, EDA), and technology transfer providers. Core offerings include vaccine manufacturing localization services, workforce training programs through EVMA-RCCN, regulatory capacity building, R&D collaboration, and market access facilitation for local manufacturers to African markets.

Differentiator

Problem solved

Functional benefit

Brands

• EVMA-RCCN: Regional Capacity Building Center - a center under EVMA focused on providing training, research, and regulatory capacity building for biomanufacturing across Africa

Products and services

• Vaccine Manufacturing Localization Coordination Services Strategic initiative establishing a sustainable vaccine manufacturing ecosystem in Egypt, ensuring consistent supply that meets local and regional health needs through stakeholder alignment, technology transfer facilitation, and capability mapping. Targets government agencies and Egyptian vaccine manufacturers.
• EVMA-RCCN Biomanufacturing Training Programs Comprehensive capacity building programs covering upstream and downstream bioprocessing, quality control, Good Manufacturing Practices (GMP), and regulatory compliance for the vaccine manufacturing workforce. Delivered via workshops, academic programs, hands-on lab training, and online courses, in partnership with Cairo University and Ain Shams University faculties of pharmacy.
• Regulatory Capacity Building Services Services that strengthen the Egyptian Drug Authority (EDA) and harmonize regulatory standards across Africa to ensure quality, safety, and efficacy of locally produced vaccines, supporting WHO Prequalification of Local Vaccine Manufacturers.
• Research and Development Collaboration Programs Joint R&D projects between EVMA-RCCN, Cairo University, Ain Shams University, and vaccine manufacturers, focusing on process optimization, novel vaccine technologies, and production efficiency enhancement.
• Government Stakeholder Coordination Platform Collaboration platform coordinating MOHP, UPA, EDA, and vaccine manufacturers to align efforts between government entities and private sector for vaccine manufacturing advancement, convened formally under Ministerial Decree No. 449 of 2025.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

17 partnerships are on record, tiered core, major, significant and flagship.

• Ministry of Health and Population (MOHP)coreStrategic or Co-development Partner · 1 January 2024MOHP is the primary governmental body overseeing public health in Egypt, implementing health policies, managing healthcare services, and driving healthcare reforms toward Universal Health Coverage by 2030. MOHP formally convened the first EVMA Committee meeting in March 2026 under Ministerial Decree No. 449 of 2025.
• Egyptian Drug Authority (EDA)coreStrategic or Co-development Partner · 1 January 2019EDA is the regulatory body for registration, licensing, inspection, and supervision of pharmaceuticals, cosmetics, and medical equipment in Egypt, established under Law No. 151/2019. EDA provides regulatory and technical support to facilitate vaccine manufacturing and enable companies to meet international standards.
• Unified Procurement Authority (UPA)coreStrategic or Co-development Partner · 1 January 2019UPA was created to streamline procurement of medical supplies across public healthcare entities, negotiating prices and ensuring cost-effective purchasing. UPA's Chairman serves as rapporteur of the Medical Industries Localization Committee, chaired by the Prime Minister. UPA email: [email protected]
• VACSERAcoreStrategic or Co-development PartnerVACSERA (The Egyptian Holding Company for Biological Products and Vaccines) is a key Egyptian vaccine manufacturer and member of EVMA. It is a major producer of vaccines and biological products in Egypt, participating in EVMA's coordination structure and RCCN training hub activities.
• Biogeneric Pharma (BPG)coreStrategic or Co-development PartnerBiogeneric Pharma is an Egyptian vaccine manufacturer and member of EVMA, contributing to the alliance's production capacity. Named alongside VACSERA, Gennvax, VBC, and others as a participating manufacturer in EVMA's governance structure.
• GennvaxcoreStrategic or Co-development PartnerGennvax is an Egyptian biotech company focused on vaccine manufacturing and a member of EVMA. It participates in the EVMA-RCCN training hub and was represented at the EVMA conference launch with a dedicated speech.
• VBC Vaccines & Biologicals CitycoreStrategic or Co-development PartnerVBC Vaccines & Biologicals City is an Egyptian vaccine manufacturer and member of EVMA. Represented at the EVMA conference launch with a dedicated speech and featured in the EVMA-RCCN training center's industry partnerships strategy.
• Cairo University Faculty of PharmacymajorStrategic or Co-development PartnerCollaborating with EVMA RCCN to integrate biomanufacturing training programs into university degree offerings, covering upstream/downstream processing, GMP, quality control, and regulatory compliance.
• Ain Shams University Faculty of PharmacymajorStrategic or Co-development PartnerPartnering with EVMA RCCN to integrate biomanufacturing training programs into academic degree offerings, supporting workforce development in vaccine manufacturing.
• EVA PharmacoreStrategic or Co-development PartnerEVA Pharma is an Egyptian pharmaceutical manufacturer and member of EVMA, listed among the Egyptian vaccine manufacturers. Represented at the EVMA conference launch with a dedicated speech.
• GyptocoreStrategic or Co-development PartnerGypto is an Egyptian vaccine manufacturer and member of EVMA. Represented at the EVMA conference launch with a dedicated speech alongside other member manufacturers.
• AspensignificantTechnology or IntegrationAspen is listed as a technology transfer provider on the EVMA website, offering technology transfer capabilities to Egyptian vaccine manufacturers. The company logo appears among technology transfer providers supporting the alliance.
• Bilthoven BiologicalssignificantTechnology or IntegrationBilthoven Biologicals (Netherlands) is listed as a technology transfer provider on the EVMA website, providing technology transfer support to Egyptian manufacturers for vaccine production.
• MinhaisignificantTechnology or IntegrationMinhai is listed as a technology transfer provider on the EVMA website, contributing to the ecosystem of international partners enabling vaccine manufacturing localization in Egypt.
• KangtaisignificantTechnology or IntegrationKangtai is listed as a technology transfer provider on the EVMA website, supporting technology transfer for vaccine manufacturing in Egypt.
• WHO / Partnerships for African Vaccine Manufacturing (PAVM)flagshipStrategic or Co-development PartnerEVMA is aligned with the WHO-supported Partnerships for African Vaccine Manufacturing (PAVM) initiative, working to accelerate Prequalification of Local Vaccine Manufacturers. The alliance aims to harmonize local vaccine production with African needs through regional capacity building.
• African UnionflagshipStrategic or Co-development PartnerEVMA's vision explicitly aligns with the African Union's 2040 vaccine manufacturing localization initiative and Agenda 2063, targeting the harmonization of local vaccine production with continental needs and positioning Egypt as a regional manufacturing hub.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• BioNTech: German biotech with active malaria and tuberculosis vaccine programs targeting African manufacturing partnerships, including modular mRNA facilities in Rwanda and Senegal. Comparable as a foreign technology partner enabling African vaccine capacity.
• Afrigen Biologics & Vaccines: South African biotech established as the WHO mRNA Technology Transfer Hub hub. Comparable as another African-led initiative building local vaccine manufacturing capacity with international partnership support.

Broad incumbents

• Aspen Pharmacare: South Africa's largest pharmaceutical manufacturer and a leading African vaccine player, with Aspen listed as a technology transfer provider for EVMA. Comparable as a continental-scale African vaccine manufacturer pursuing export markets.
• Bharat Biotech: Indian vaccine manufacturer with broad WHO-prequalified portfolio including COVID-19 and rotavirus vaccines. Comparable as an established emerging-market vaccine exporter that EVMA-aligned manufacturers must compete with in Africa and the Middle East.
• Biological E: Major Indian vaccine and biopharmaceutical manufacturer with WHO Prequalified products supplying UNICEF and African tenders. Comparable as a high-volume emerging-market vaccine exporter competing for the same markets EVMA targets.
• Sinovac Biotech: Major Chinese vaccine manufacturer with WHO-prequalified COVID-19 and influenza vaccines widely distributed in Africa. Comparable as a global low-cost supplier competing for the African immunization contracts EVMA aims to capture locally.
• Sinopharm: State-owned Chinese pharmaceutical group with large WHO-prequalified vaccine portfolio and significant Africa distribution footprint. Comparable as a state-aligned, scaled vaccine manufacturer competing for African tenders.
• Serum Institute of India: The world's largest vaccine manufacturer by doses, supplying large volumes to African immunization programs. Comparable as the dominant low-cost vaccine exporter EVMA's members must compete against in African tenders.
• Institut Pasteur: Historic French vaccine research and manufacturing institution with WHO collaboration and African laboratory network. Comparable as a long-standing public-sector vaccine R&D and manufacturing body operating across borders.

Direct peers

• VACSERA (Egyptian Holding Company for Biological Products and Vaccines): Egypt's largest state-owned vaccine manufacturer and a core EVMA member. Most directly comparable as it is both a participant in the alliance and a key beneficiary of EVMA's localization and export strategy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Egyptian Vaccine Manufacturers Alliance